New mRNA flu shot passes first safety test in small study
NCT ID NCT05755620
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This early-stage study tested a single-dose mRNA flu vaccine in 50 healthy adults aged 18 to 49. The goal was to check safety and see how well the vaccine triggers an immune response compared to a standard flu shot. Participants received one of three doses (10, 25, or 50 mcg) or a licensed flu vaccine for comparison.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27704, United States
Conditions
Explore the condition pages connected to this study.